Acadia Pharmaceuticals is a specialty pharmaceutical company focused on treatments for central nervous system disorders, combining marketed products with ongoing development programs. Market capitalization is roughly $4.98 billion and the stock trades on NasdaqGS within the Pharmaceutical Preparations industry.
Top-line performance has been consistently positive: revenue rose from $205.8 million in CY2024Q1 to $307.96 million in CY2026Q2, an increase of about 50%. Year‑over‑year growth in recent quarters has run from roughly high single digits to the mid‑teens (CY2026Q2 YoY +16.4%). GAAP diluted EPS has been more variable, ranging from $0.02 (CY2026Q1) to $0.42 (CY2025Q3), and GAAP EPS trends are not accelerating.
Technically and institutionally, the company looks different than a typical small-cap biotech. The stock completed a 252-session base that ended 2026-08-04 and broke out on 2026-08-05, reclaimed the 200-day average on 2026-06-24, and recorded base demand roughly twice its prior 30-day average. Institutional sponsorship is concentrated, with roughly 99.8% of shares reported held by institutions across 479 reporting holders, and accumulation and trend metrics score strongly, supporting the stock's leadership within the Biotech Therapeutics theme.
Why now
The breakout above a 252-session base in early August, recent reclamation of the 200-day average, and elevated demand volume during the base make the timing notable, while heavy institutional ownership and a three‑month excess return versus the S&P 500 confirm near-term market interest.
The setup
Last close was $28.89, just above the base resistance/pivot at $28.35, with price slightly outside the initial pivot band; the setup is a valid Stage 1→2 breakout but not actionable inside the initial entry zone. The stock sits above its 50- and 200-day averages (50-day 26.84, 200-day 24.37), RSI is neutral at 53.9, up/down volume over 50 days is positive, and short-term demand ratios show constructive buying.
Revenue trajectory
Full-year revenue with year-over-year growth. Solid bars are calendar-year actuals from SEC EDGAR filings (XBRL); dashed bars are analyst consensus via Yahoo Finance (20 analysts), which is published two fiscal years out.Earnings trajectory
Solid bars are quarterly GAAP diluted EPS from SEC EDGAR filings. Dashed bars are analyst consensus, which is typically adjusted (non-GAAP). The two are measured differently, so a step between the last actual and the first estimate usually reflects that change in basis rather than a change in the business.Analyst full-year EPS consensus (typically adjusted): FY'26E $0.60 (-28%) · FY'27E $0.89 (+48%) — 20 analysts
Risks
Revenue growth has slowed from the outsized gains seen in early 2024 and shows no acceleration, leaving execution risk if end-market demand softens. GAAP diluted EPS has been volatile quarter to quarter, which can complicate near-term earnings visibility. Extremely high institutional ownership concentration can amplify price moves if large holders change position, and biotech names remain exposed to regulatory and commercial setbacks typical of the sector.
Framework fit
CANSLIM
6/7- CCurrent quarterly GAAP EPS growth ≥ 25%+12%✕
- AAnnual GAAP EPS growth ≥ 25%+69%✓
- NNew highs — within 15% of 52-week high-5.5%✓
- SSupply/demand — up-day volume leads1.76x✓
- LLeader — outperforming the S&P 500+16% 6m✓
- IInstitutional sponsorshipmodel score 9/10✓
- MMarket in a confirmed uptrendConfirmed uptrend✓
Minervini Trend Template
6/7Stage 2 confirmation checklist: price versus rising long-term moving averages and the 52-week range.
Weinstein Stage
Broke above a 252-session base on 2026-08-05. Breakout volume was 2.69x its prior 30-day average. Strongest qualifying base demand was 2.08x on 2026-05-07.